Today, January 28, the Nebuflag study is being launched at the CHRU in Tours, France.
This is the 3rd stage of a larger research project, led by a consortium of European researchers*, and financed by European funds, notably Horizon 2020. This study is the 1st to be carried out on healthy, spontaneously breathing volunteers. One of the aims is to test the human response to the treatment currently being developed, called FLAMOD. This is a flagellin aerosol therapy for the treatment of drug-resistant bacterial pneumonia.
Pneumonia is a type of respiratory tract infection that causes inflammation of the pulmonary alveoli – in short, it prevents breathing. Pneumonia is currently the third leading cause of death worldwide, and particularly affects children and the elderly. A major complicating factor for effective treatment is the emergence of antimicrobial resistance (AMR), where the bacteria responsible for pneumonia are resistant to the antibiotics normally used to treat and eliminate the infection.
The World Health Organization (WHO) estimates that bacterial infections due to antimicrobial resistance will become the leading cause of death worldwide by 2050. Our researchers are working hard to find effective alternative therapies. This is the challenge facing the FAIR** consortium, which is studying therapies that could be used as an alternative to antibiotic treatment of pneumonia.
Our experts today are :
Valérie Gissot, delegated physician, CIC clinical investigation center, CHRU Tours.
Antoine Guillon, intensive care physician, Tours University Hospital, INSERM U110 Centre d’Étude des Pathologies Respiratoires.
They tell us more about the NEBUFLAG study, which is being launched today at the CHRU de Tours.
* Consortium members: Inserm Freie Universität Berlin, Epithelix, Aerogen, Statens Serum Institut, CHU Tours, Amsterdam UMC, Université de Lille, University of Southampton, European Respiratory Society, Inserm | Cellule Europe, Inserm Transfert
**Flagellin aerosol therapy as an immunomodulatory adjunct to the antibiotic treatment of drug-resistant bacterial pneumonia (FAIR)
The consortium is coordinated by Jean-Claude Sirard, Team Leader at the Lille Center for Infection and Immunity.
